Oseltamivir pharmacokinetics and clinical experience in neonates and infants during an outbreak of H1N1 influenza A virus infection in a neonatal intensive care unit

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3833-3840

  Standing, Joseph F ^a   Nika, Angela ^b   Tsagris, Vasileios ^b   Kapetanakis, Ioannis ^b   Maltezou, Helena C ^c   Kafetzis, Dimitris A ^b   Tsolia, Maria N ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ATHENS   (Greece)

^c Hellenic Center for Disease Control and Prevention   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR;

ALLOMETRY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DEHYDRATION; DIARRHEA; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE INCREASE; DRUG TRANSFORMATION; DRUG WITHDRAWAL; EPIDEMIC; HIGH RISK PATIENT; HUMAN; IC 50; INFANT; INFECTION PREVENTION; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; LIVER FUNCTION TEST; NEWBORN; NEWBORN INTENSIVE CARE; NONHUMAN; PREMATURITY; PRIORITY JOURNAL; SIDE EFFECT; STEADY STATE;

ANTIVIRAL AGENTS; DISEASE OUTBREAKS; FEMALE; HUMANS; INFANT, NEWBORN; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; INTENSIVE CARE UNITS; MALE; OSELTAMIVIR;

EID: 84862572365     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00290-12     Document Type: Article

References (36)

1. Aarons L. 2005. Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed. Br. J. Clin. Pharmacol. 60:581-583.
2. Abdel-Rahman SM, Newland JG, Kearns GL. 2011. Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant. Paediatr. Drugs 13:19-31.
3. Acosta E, Jester P, Gal P. 2010. Oseltamivir dosing for influenza infection in premature neonates. J. Infect. Dis. 202:563-566.
4. Beal SL, Sheiner LB, Boeckmann A, Bauer RJ. 2011. NONMEM users guide (1989-2011). Icon Development Solutions, Ellicott City, MD.
5. Beal SL. 2001. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 28:481-504.
6. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. 2011. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 13:143-151.
7. Centers for Disease Control and Prevention. 2011. Antiviral agents for the treatment and chemoprophylaxis of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommend. Rep. 60:1-24.
8. Davies BE. 2010. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J. Antimicrob. Chemother. 65(Suppl 2):ii5-ii10.
9. Hanshaoworakul W, et al. 2009. Severe human influenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome. PLoS One 4:e6051. doi:10.1371/journal.pone.0006051.
10. Hayden FG, et al. 1999. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 282:1240-1246.
11. He G, Massarella J, Ward P. 1999. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin. Pharmacokinet. 37:471-484.
12. Heinonen S, et al. 2010. Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial. Clin. Infect. Dis. 51:887-894.
13. Kaiser L, et al. 2003. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch. Intern. Med. 163:1667-1672.
14. Kearns GL, et al. 2003. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349:1157-1167.
15. Kimberlin D, et al. 2009. Oseltamivir (OST) and OST carboxylate (CBX) pharmacokinetics (PK) in infants: interim results from a multicenter trial, abstr 1041. Abstr. 47th Annu. Meet. Infect. Dis. Soc. Am. (IDSA), Philadelphia, PA, 31 October 2009.
16. McGeer A, et al. 2007. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin. Infect. Dis. 45:1568-1575.
17. Munoz FM, et al. 1999. Influenza A virus outbreak in a neonatal intensive care unit. Pediatr. Infect. Dis. J. 18:811-815.
18. Nicholson KG, et al. 2000. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 355:1845-1850.
19. Oo C, et al. 2003. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years. Eur. J. Clin. Pharmacol. 59:411-415.
20. Oxford J. 2005. Oseltamivir in the management of influenza. Exp. Opin. Pharmacother. 6:2493-2500.
21. Price PS, et al. 2003. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit. Rev. Toxicol. 33:469-503.
22. Rayner CR, Chanu P, Gieschke R, Boak LM, Jonsson EN. 2008. Population pharmacokinetics of oseltamivir when coadministered with probenecid. J. Clin. Pharmacol. 48:935-947.
23. Rhodin MM, et al. 2009. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr. Nephrol. 24:67-76.
24. Ribbing J, Jonsson EN. 2004. Power, selection bias and predictive performance of the population pharmacokinetic covariate model. J. Pharmacokinet. Pharmacodyn. 31:109-134.
25. Schentag JJ, Hill G, Chu T, Rayner CR. 2007. Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects. J. Clin. Pharmacol. 47:689-696.
26. Sert A, Yazar D, Odabas H, Bilgin H. 2010. An unusual cause of fever in a neonate: influenza A (H1N1) virus pneumonia. Pediatr. Pulmonol. 45:734-736.
27. Shi D, Yang D, Prinssen EP, Davies BE, Yan B. 2011. Surge in expression of carboxylesterase 1 during the neonatal stage enables a rapid gain of the capacity to activate the anti-influenza prodrug oseltamivir. J. Infect. Dis. 203:937-942.
28. Thompson WW, et al. 2004. Influenza-associated hospitalizations in the United States. JAMA 292:1333-1340.
29. Thompson WW, et al. 2003. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289:179-186.
30. Tod M, Jullien V, Pons G. 2008. Facilitation of drug evaluation in children by population methods and modelling. Clin. Pharmacokinet. 47:231-243.
31. Treanor JJ, et al. 2000. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 283:1016-1024.
32. Whitley RJ, et al. 2001. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 20:127-133.
33. Wilkinson D, Buttery J, Andersen C. 2006. Influenza in the neonatal intensive care unit. J. Perinatol. 26:772-776.
34. World Health Organization. 2010. WHO guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses. World Health Organization, Geneva, Switzerland.
35. Yang D, et al. 2009. Human carboxylesterases HCE1 and HCE2: ontogenic expression, interindividual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem. Pharmacol. 77:238-247.
36. Yu H, et al. 2010. Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China. BMJ 341:c4779. doi:10.1136/bmj.c4779.